Sunday, December 13, 2015

ABIRATERONE EFFECTIVE ALSO IN HIGH GLEAN SCORE PROSTATE CANCER

Tags

In 1,048 prostate cancer patients previously treated with docetaxel, and 996 metastatic, castration-resistant patients, treatment with the androgen-lowering drug abiraterone acetate (Zytiga) led to longer overall disease control, even when a very high Gleason score indicated especially aggressive cancer.
Study Findings
Results recently published by Fizazi et al in the Annals of Oncology show that for patients with Gleason score greater than 8, postdocetaxel treatment with abiraterone extended progression-free survival from 5.5 months to 6.4 months, and prechemotherapy abiraterone treatment extended progression-free survival from 8.2 months to 16.5 months.
“We have the idea that with an unfavorable Gleason score, we have to immediately reach for the harshest chemicals, but this study shows that's not always the case. Abiraterone is easier to take, has fewer side effects, and shows prolonged survival,” said Thomas Flaig, MD, Associate Director for Clinical Research at the University of Colorado Cancer Center, and Associate Professor of Medicine at the University of Colorado School of Medicine.
Dr. Flaig was coinvestigator of clinical trials that led to U.S. Food and Drug Administration (FDA) approval of abiraterone acetate, and with collaborators, continues to explore the best use of the drug. Previous work showed that the drug is useful even in cases of prostate cancer that has metastasized to the liver, another poor prognostic sign. The current study extends this finding to include all aggressive prostate cancers marked by high Gleason score.
“The main thing this analysis does is help us better understand how to use this new agent. Certainly there are cases in which cytotoxic chemotherapies are appropriate. But this study points to a broad use of this oral hormonal agent,” Dr. Flaig said.
In addition to extending the duration of progression-free survival, this study showed greater overall survival and better control of prostate-specific antigen with abiraterone treatment. The treatment is used in combination with prednisone.
“Thus, the Gleason score at the time of diagnosis should not factor into the decision to prescribe or treat a patient with metastatic castration-resistant prostate cancer with abiraterone acetate plus prednisone,” the authors concluded.

Artikel Terkait


EmoticonEmoticon